A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's. The aims of the trial are to affirm potential therapeutic efficacy and safety observed in earlier clinical trials and assess the potential to modify the course of disease. The drug will be compared to placebo and administered orally to patients once a day for 78 weeks.

NCT Number	NCT06964230
Lead Sponsor	T3D Therapeutics, Inc.
Conditions	Alzheimer's Disease
Enrollment	376 participants
Start Date	2026-10-26
Primary Completion	2031-04 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2025-05-09